Literature DB >> 22931338

Anti-CD20 antibody therapy for B-cell lymphomas.

Ronald P Taylor, Margaret A Lindorfer, Clive S Zent.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22931338     DOI： 10.1056/NEJMc1207378

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  5 in total

1.  Amplification of CD20 Cross-Linking in Rituximab-Resistant B-Lymphoma Cells Enhances Apoptosis Induction by Drug-Free Macromolecular Therapeutics.

Authors:  Lian Li; Jiyuan Yang; Jiawei Wang; Jindřich Kopeček
Journal:  ACS Nano       Date:  2018-04-02       Impact factor: 15.881

2.  Targeting macrophages for enhancing CD47 blockade-elicited lymphoma clearance and overcoming tumor-induced immunosuppression.

Authors:  Xu Cao; Yingyu Wang; Wencan Zhang; Xiancai Zhong; E Gulsen Gunes; Jessica Dang; Jinhui Wang; Alan L Epstein; Christiane Querfeld; Zuoming Sun; Steven T Rosen; Mingye Feng
Journal:  Blood       Date:  2022-06-02       Impact factor: 25.476

3.  Association of rituximab with graphene oxide confers direct cytotoxicity for CD20-positive lymphoma cells.

Authors:  Chengke Luo; Zhenghao Deng; Lan Li; Frederic Clayton; Alexander L Chen; Ran Wei; Rodney Miles; Deborah M Stephens; Martha Glenn; Xiyang Wang; Peter E Jensen; Xinjian Chen
Journal:  Oncotarget       Date:  2016-03-15

4.  Construction and characterization of an anti-CD20 mAb nanocomb with exceptionally excellent lymphoma-suppressing activity.

Authors:  Hua-Fei Li; Cong Wu; Ting Chen; Ge Zhang; He Zhao; Chang-Hong Ke; Zheng Xu
Journal:  Int J Nanomedicine       Date:  2015-07-30

5.  Synergistic anti-tumor therapy by a comb-like multifunctional antibody nanoarray with exceptionally potent activity.

Authors:  Huafei Li; Yun Sun; Di Chen; He Zhao; Mengxin Zhao; Xiandi Zhu; Changhong Ke; Ge Zhang; Cheng Jiang; Li Zhang; Fulei Zhang; Huafeng Wei; Wei Li
Journal:  Sci Rep       Date:  2015-10-28       Impact factor: 4.379
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.